News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
522,945 Results
Type
Article (12950)
Company Profile (143)
Press Release (509851)
Multimedia
Podcasts (15)
Webinars (6)
Section
Business (177536)
Career Advice (385)
Deals (27343)
Drug Delivery (16)
Drug Development (58461)
Employer Resources (24)
FDA (10738)
Job Trends (9553)
News (255865)
Policy (19867)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (896)
Accelerated approval (31)
ADA (24)
Adcomms (3)
Allergies (113)
Alliances (34699)
ALS (178)
Alzheimer's disease (1228)
Antibody-drug conjugate (ADC) (305)
Approvals (11405)
Artificial intelligence (360)
ASCO (192)
Autoimmune disease (235)
Automation (30)
Bankruptcy (276)
Best Places to Work (7791)
BIO (43)
BIOSECURE Act (1)
Biosimilars (134)
BioSpace Insights (26)
Biotechnology (91)
Bladder cancer (164)
Brain cancer (35)
Breast cancer (591)
Cancer (4226)
Cardiovascular disease (279)
Career advice (315)
Career pathing (3)
CAR-T (197)
CDC (7)
Celiac Disease (1)
Cell therapy (563)
Cervical cancer (38)
Clinical research (52843)
Collaboration (1379)
Commercialization (3)
Company closure (1)
Compensation (1471)
Complete response letters (42)
COVID-19 (1021)
CRISPR (69)
C-suite (785)
Cystic fibrosis (92)
Data (6506)
Denatured (5)
Depression (112)
Dermatology (77)
Diabetes (430)
Diagnostics (4581)
Digital health (38)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (183)
Drug pricing (25)
Drug shortages (3)
Duchenne muscular dystrophy (191)
Earnings (80415)
Editorial (4)
Employer branding (5)
Employer resources (23)
Events (93246)
Executive appointments (732)
FDA (13733)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (27)
Funding (1047)
Gene editing (136)
Generative AI (15)
Gene therapy (387)
GLP-1 (435)
Government (1403)
Grass and pollen (4)
Guidances (352)
Healthcare (10810)
Hematology (109)
HIV (57)
Huntington's disease (41)
IgA nephropathy (73)
Immunology and inflammation (154)
Immuno-oncology (65)
Indications (180)
Infectious disease (1234)
Inflammatory bowel disease (154)
Inflation Reduction Act (6)
Influenza (92)
Intellectual property (258)
Interviews (53)
IPO (13393)
IRA (4)
Job creations (2168)
Job search strategy (295)
JPM (7)
Kidney cancer (18)
Labor market (24)
Layoffs (122)
Leadership (3)
Legal (5458)
Licensing (7)
Liver cancer (55)
Longevity (18)
Lung cancer (578)
Lymphoma (319)
Machine learning (29)
Management (4)
Manufacturing (610)
Marketing (11)
MASH (138)
Medical device (9473)
Medtech (9626)
Mergers & acquisitions (15039)
Metabolic disorders (913)
mRNA (68)
Multiple sclerosis (130)
NASH (5)
Neurodegenerative disease (332)
Neuropsychiatric disorders (48)
Neuroscience (2380)
Neurotech (1)
NextGen: Class of 2026 (3556)
Non-profit (1343)
Now hiring (7)
Obesity (325)
Opinion (36)
Ovarian cancer (176)
Pain (206)
Pancreatic cancer (227)
Parkinson's disease (298)
Partnered (14)
Patents (499)
Patient recruitment (551)
Peanut (39)
People (42818)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (16613)
Phase 2 (23453)
Phase 3 (16667)
Pipeline (8135)
Policy (40)
Postmarket research (1794)
Preclinical (7054)
Press Release (37)
Prostate cancer (221)
Psychedelics (18)
Radiopharmaceuticals (213)
Rare diseases (682)
Real estate (3262)
Recruiting (11)
Regulatory (16576)
Reports (29)
Research institute (929)
Resumes & cover letters (59)
Rett syndrome (44)
RNA editing (8)
RSV (53)
Schizophrenia (114)
Series A (174)
Series B (130)
Service/supplier (5)
Sickle cell disease (72)
Special edition (10)
Spinal muscular atrophy (167)
Sponsored (12)
Startups (2203)
Stomach cancer (4)
Supply chain (54)
Tariffs (16)
The Weekly (10)
Vaccines (416)
Venture capital (29)
Weight loss (152)
Women's health (83)
Worklife (1)
Date
Today (97)
Last 7 days (590)
Last 30 days (1830)
Last 365 days (21444)
2026 (13401)
2025 (21504)
2024 (25320)
2023 (29156)
2022 (37244)
2021 (40021)
2020 (36231)
2019 (26495)
2018 (19754)
2017 (20800)
2016 (19684)
2015 (26178)
2014 (23046)
2013 (19304)
2012 (21317)
2011 (21611)
2010 (21292)
Location
Africa (282)
Alabama (74)
Alaska (2)
Arizona (317)
Arkansas (14)
Asia (21359)
Australia (2795)
California (12403)
Canada (3276)
China (712)
Colorado (517)
Connecticut (443)
Delaware (279)
Europe (35722)
Florida (1849)
Georgia (386)
Hawaii (3)
Idaho (47)
Illinois (801)
India (57)
Indiana (430)
Iowa (14)
Japan (460)
Kansas (108)
Kentucky (31)
Louisiana (33)
Maine (42)
Maryland (1281)
Massachusetts (8299)
Michigan (324)
Minnesota (599)
Mississippi (4)
Missouri (90)
Montana (22)
Nebraska (12)
Nevada (116)
New Hampshire (64)
New Jersey (2946)
New Mexico (15)
New York (3018)
North Carolina (1352)
North Dakota (6)
Northern California (6263)
Ohio (307)
Oklahoma (14)
Oregon (16)
Pennsylvania (2358)
Puerto Rico (21)
Rhode Island (32)
South America (502)
South Carolina (77)
South Dakota (1)
Southern California (5072)
Tennessee (136)
Texas (1982)
United States (41142)
Utah (371)
Vermont (1)
Virginia (175)
Washington D.C. (41)
Washington State (975)
West Virginia (1)
Wisconsin (82)
522,945 Results for "neuron23 inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox Foundation
June 17, 2026
·
6 min read
Press Releases
Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology
March 26, 2025
·
3 min read
Business
Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
Neuron23™ Inc. today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO).
August 22, 2023
·
3 min read
Press Releases
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
November 19, 2024
·
7 min read
Press Releases
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease
June 24, 2025
·
5 min read
Press Releases
Neuron23 to Present Phase 1 Healthy Volunteer Data of NEU-411, a Brain-penetrant LRRK2 Inhibitor, at AD/PD™ 2025
March 24, 2025
·
3 min read
Press Releases
Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
November 19, 2024
·
4 min read
Business
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
Neuron23™ Inc. and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
Press Releases
Neuron23 Announces First-in-human Dose in Phase 1 Clinical Trial of NEU-111, a TYK2 Inhibitor with Best-in-class Potential for Immune-mediated Inflammatory Disorders
December 4, 2024
·
2 min read
Business
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc. today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
1 of 52,295
Next
